Explore our certified pilot-to-commercial solutions engineered to overcome chemical dissolution barriers, metabolic clearance, and membrane permeability hurdles.
High-precision HPLC, HPTLC, and LC-MS method development to quantify active compound recovery, degradation kinetics, and bio-distribution metrics.
View Full Specifications
Empirical botanical screening identifying high-density polyphenol, alkaloid, and saponin isomers with targeted intrinsic permeability profiles.
View Full Specifications
Full-scope GCP-compliant clinical evaluation quantifying human pharmacokinetic curves, AUC0-t plasma absorption, and dose-response bio-equivalency.
View Full Specifications
Rigorous rodent and non-rodent model evaluations establishing comparative bioavailability metrics, maximum plasma concentration (Cmax), and toxicity thresholds.
View Full Specifications
Caco-2 monolayer transport and PAMPA assays providing predictive membrane permeability, P-gp transporter efflux quantification, and cellular uptake rates.
View Full Specifications
Systematic chemical fingerprinting identifying seasonal variance, geo-authentic origin potency, and harvest-timing impact on active compound integrity.
View Full Specifications
Comprehensive quality grading of botanical raw materials, screening for contaminants, secondary metabolites, and baseline bio-accessibility profiles.
View Full Specifications
Supercritical CO2, membrane partition, and column chromatography process development ensuring maximized preservation of therapeutic target molecules.
View Full SpecificationsOver 70% of emerging pharmaceutical new chemical entities (NCEs) and more than 85% of active botanical therapeutic substances suffer from low oral bioavailability. As a dedicated OEM bioavailability manufacturer, MedGence provides systematic biopharmaceutical engineering to overcome the Biopharmaceutics Classification System (BCS) Class II and IV boundaries.
Hydrophobic phytochemicals like Curcumin, Resveratrol, Quercetin, and Apigenin possess high crystal lattice energy, preventing disintegration and dissolution in the aqueous lumen of the gastrointestinal tract. Without solubilization, gastrointestinal transit occurs without mucosal absorption. Our proprietary solubilization strategies leverage solid dispersions, cyclodextrin inclusion, and lipid micro-emulsions to amplify dissolution kinetics by over 1,200% based on the classic Noyes-Whitney diffusion model.
Even when dissolved, active ingredients encounter transmembrane resistance from multidrug resistance protein transporters, specifically ATP-binding cassette transporter P-glycoprotein (P-gp / ABCB1), coupled with rapid phase-I cytochrome P450 (CYP3A4) and phase-II glucuronidation. Through precision co-formulation with biocompatible bio-enhancers and lipid vehicles, our delivery matrices shield molecules, circumventing mucosal efflux pumps and extending intestinal residence.
Orally absorbed compounds typically transit via mesenteric venules into the portal vein, exposing fragile actives to aggressive hepatic first-pass metabolism that deactivates up to 95% of active moieties before systemic distribution. We design specialized Self-Nanoemulsifying Drug Delivery Systems (SNEDDS) and chylomicron-mimicking lipid platforms that trigger lymphatic uptake via Peyer's patches, transporting uncompromised parent compounds directly into systemic blood circulation.
The worldwide demand for high-potency bioavailability-enhanced formulations is accelerating exponentially across North America, the European Union, and the Asia-Pacific region, driven by strict regulatory expectations, consumer sophistication, and therapeutic dosage reduction mandates.
Global regulatory bodies, including the US FDA (via 21 CFR Part 111 and NDIN guidance) and EFSA (European Food Safety Authority), are demanding substantiation for structure-function claims. Generic extracts with low systemic absorption are losing market dominance to clinically validated, trademarked bioactive ingredients. Brands partnering with MedGence leverage clinical pharmacokinetic (PK) endpoints—such as Area Under the Curve (AUC), Cmax, and Tmax—to defend premium pricing and validate consumer efficacy.
The boundaries between nutraceuticals and botanical pharmaceuticals are dissolving. Global pharmaceutical conglomerates are advancing botanical Investigational New Drug (IND) applications that require rigorous multi-constituent chromatographic standardization, cGMP manufacturing controls, and human pharmacokinetic modeling. Our facility bridges the gap between traditional herbal wisdom and rigorous ICH Q8/Q9/Q10 Quality by Design (QbD) pharmaceutical CDMO standards.
Modern therapeutic delivery faces high attrition due to "pill fatigue." Delivering an effective dose of native un-enhanced herbal extract often mandates consuming four to eight capsules daily. By engineering targeted bioavailability platforms that enhance systemic absorption five-fold to thirty-fold, our OEM manufacturing services consolidate large therapeutic regimens into a single, compact once-daily softgel, liquid vial, or micro-granule sachet.
Bioavailability optimization is not a one-size-fits-all formula. The physicochemical structure, LogP lipophilicity, melting temperature, and enzymatic cleavage vulnerabilities of each molecule dictate the choice of delivery platform. MedGence masters four industrial-scale enhancement vectors.
Self-Nanoemulsifying Drug Delivery Systems (SNEDDS) blend isotropic mixtures of natural oils, surfactants, and co-surfactants. Upon contact with gastrointestinal fluid under mild peristaltic agitation, they spontaneously assemble into transparent nano-emulsions with droplet diameters below 50 nm. This prevents crystallization, provides immense interfacial surface area, and facilitates spontaneous mixed micelle formation for rapid enterocyte uptake.
By complexing individual plant polyphenol molecules with pharmaceutical-grade phosphatidylcholine at precise stoichiometric ratios (1:1 or 1:2), our Phytosome technology produces molecularly integrated complexes. The polar headgroup complexes with phenolic hydroxyls, while lipophilic fatty acid tails interface cleanly with human intestinal enterocyte lipid membranes, facilitating effortless passive transcellular crossing.
Using state-of-the-art Hot-Melt Extrusion (HME) and solvent-spray drying, we disperse crystalline phytochemicals at a molecular level into hydrophilic polymer matrices (such as HPMC-AS, PVP-VA, or Soluplus). This eliminates the thermodynamic crystal lattice barrier, generating an ultra-high energy amorphous state that creates sustained supersaturation in intestinal fluid ("spring-and-parachute" effect) without precipitate reformation.
Hydrophobic active molecules are encapsulated inside the cone-shaped lipophilic cavities of native and modified cyclic oligosaccharides, such as Hydroxypropyl-Beta-Cyclodextrin (HP-β-CD) and Gamma-Cyclodextrin. The exterior hydrophilic surface interacts seamlessly with luminal fluids, acting as true molecular shuttles that transport insolubles through the unstirred water layer directly to the epithelial brush border.
| Delivery Technology | Target Compound Profile | Mean Bioavailability Increase | Ideal Dosage Delivery Forms | Stability & Scalability |
|---|---|---|---|---|
| Lipid SNEDDS / SMEDDS | Highly lipophilic (LogP > 4), BCS Class II | 600% - 1,800% vs Native | Softgels, Liquid Vials, Lipid-Caps | Excellent thermodynamic stability |
| Phospholipid Phytosomes | Polyphenolics, Flavonoids, Terpenes | 400% - 900% vs Native | Vegetarian Capsules, Tablets, Stickpacks | High moisture sensitivity; blister packed |
| Hot-Melt Extrusion (ASD) | High melting point crystalline actives | 500% - 1,400% vs Native | Compressed Tablets, Extended-Release | Exceptional physical shelf-stability |
| HP-Beta-Cyclodextrins | Aromatic, small molecule structures | 300% - 800% vs Native | Effervescent, Soluble Powders, Sprays | High water solubility & quick onset |
MedGence operates under strict international cGMP quality management systems, harmonizing documentation for effortless registration across the United States FDA, European Union EMA, Australian TGA, and China NMPA jurisdictions.
Every production batch undergoes comprehensive chromatographic fingerprinting via high-performance thin-layer chromatography (HPTLC), validated HPLC-DAD, and GC-MS. We test and certify heavy metal limits (ICP-MS for Pb, As, Cd, Hg conforming to USP <232> and <233>), pesticide residues (over 450 compounds screened via LC-MS/MS conforming to USP <561>), residual solvents (USP <467>), and microbial limits.
We empower our OEM / ODM partners with comprehensive technical documentation packages: Certificate of Analysis (COA), Master Manufacturing Records (MMR), stability testing protocols conforming to ICH Q1A(R2) under accelerated and real-time conditions, safety toxicology packages (LD50, Ames bacterial reverse mutation test, in vitro micronucleus test), and botanical origin provenance documentation.
Commercial competitive advantage relies on exclusivity. MedGence operates on an entrusted, confidential contract development and manufacturing model. All client proprietary formulations, custom carrier ratios, patented excipient compositions, and manufacturing parameters are shielded under rigorous bilateral non-disclosure agreements, backed by isolated pilot production bays.
Our engineered bioavailability platforms integrate cleanly across three primary market segments, delivering measurable physical absorption improvements that validate consumer health outcomes.
High-value anti-aging and metabolic health compounds such as NAD+ precursors (NMN, NR), Resveratrol, PQQ, Spermidine, CoQ10, and Berberine suffer from degradation in acidic gastric media or excessive hepatic conversion. Our liposomal and SNEDDS dosage configurations protect molecules through the stomach, facilitating direct intestinal absorption. This allows consumer brands to demonstrate verifiable serum level elevation with lower overall milligram dosages.
Drawing on our heritage of modernizing 83 classic Traditional Chinese Medicine formulas and obtaining 56 hospital preparation registrations, we support biopharma partners advancing botanical drug candidates. Our platform resolves common formulation deadlocks, including insolubility during dose-escalation toxicity studies and uneven batch-to-batch plasma absorption in human Phase I through Phase IV clinical protocols.
Botanical active ingredients targeting deep dermal fibroblasts must breach the lipophilic stratum corneum. We manufacture specialized nano-vesicles, transfersomes, and ethosomes that encapsulate sensitive natural actives like Bakuchiol, Ginsenosides, and Centella Asiatica triterpenes. These nano-carriers provide enhanced skin penetration, sustained intracellular release, and complete resistance to light and oxidative degradation.
MedGence is actively investing in AI-driven formulation engineering, precision-targeted carrier materials, and green continuous manufacturing to ensure long-term market competitiveness for our global clientele.
Implementing machine-learning algorithms that analyze 3D chemical structures, molecular surface charge, and LogP to predict optimal surfactant-lipid combinations in silico, slashing R&D formulation discovery timelines by up to 60%.
Developing dual-layer biopolymer shells responsive specifically to colonic pH shifts and microbial azoreductase enzymes, delivering targeted release for gut microbiome restoration and inflammatory bowel therapies.
Transitioning batch synthesis to high-throughput continuous-flow microfluidic reactors, achieving ultra-narrow polydispersity indexes (PDI < 0.1) and uniform batch-to-batch nanoparticle replication at industrial scales.
Eliminating synthetic organic solvents through supercritical fluid chromatography and solvent-free high-shear melt-granulation, fulfilling the emerging global demand for clean-label, eco-responsible therapeutics.
Find concrete answers regarding manufacturing capabilities, analytical methodology, minimum batch scales, and intellectual property safety.
Connect directly with our engineering teams to transition your poorly soluble compounds into stabilized, bio-accessible commercial dosage formats.
Analytical validation confirming chemical integrity, dissolution profiles, and degradation markers for regulatory submissions.
Request Quotation
High-throughput screening isolating targeted bio-active molecules from botanical biomass with high industrial extraction efficiency.
Request Quotation
Human pharmacokinetic validation programs tracking clinical bio-distribution, half-life parameters, and therapeutic outcome markers.
Request Quotation
Rigorous non-human PK evaluations demonstrating comparative plasma concentration AUC curves and organ distribution dynamics.
Request Quotation
Caco-2 cell permeability testing and artificial membrane transport models to calculate accurate transcellular permeability kinetics.
Request Quotation
Comparative agronomic profiling identifying optimal harvesting seasons and geographic regions yielding maximum therapeutic marker density.
Request Quotation
Complete botanical raw material qualification ensuring absence of adulterants, heavy metals, and residual chemical pesticides.
Request Quotation
Specialized extraction optimization isolating delicate active moieties without thermal degradation or secondary metabolite losses.
Request QuotationEngage our PhD formulation scientists to evaluate your target compound, overcome dissolution barriers, and design a scalable commercial OEM manufacturing roadmap. Submit your project requirements under non-disclosure.
